Published in Atherosclerosis on May 01, 2003
Lipoprotein genotype and conserved pathway for exceptional longevity in humans. PLoS Biol (2006) 3.12
Candidate-based proteomics in the search for biomarkers of cardiovascular disease. J Physiol (2004) 2.42
A list of candidate cancer biomarkers for targeted proteomics. Biomark Insights (2007) 2.39
Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab (2007) 1.38
APOC3 promoter polymorphisms C-482T and T-455C are associated with the metabolic syndrome. Arch Med Res (2007) 1.22
Quantitative analysis of intact apolipoproteins in human HDL by top-down differential mass spectrometry. Proc Natl Acad Sci U S A (2010) 1.18
Apolipoprotein C-III as a Potential Modulator of the Association Between HDL-Cholesterol and Incident Coronary Heart Disease. J Am Heart Assoc (2012) 1.15
Lack of association between apolipoprotein C3 gene polymorphisms and risk of coronary heart disease in a Han population in East China. Lipids Health Dis (2011) 1.02
Triglyceride-rich lipoprotein-associated apolipoprotein C-III production is stimulated by plasma free fatty acids in humans. Arterioscler Thromb Vasc Biol (2008) 0.95
Characterization of apolipoprotein and apolipoprotein precursors in pancreatic cancer serum samples via two-dimensional liquid chromatography and mass spectrometry. J Chromatogr A (2007) 0.94
Plasma apolipoprotein C-III levels, triglycerides, and coronary artery calcification in type 2 diabetics. Arterioscler Thromb Vasc Biol (2015) 0.92
Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease. J Am Heart Assoc (2013) 0.83
Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome. Diabetes Care (2008) 0.82
Individual differences in hyperlipidemia and vitamin E status in response to chronic alcohol self-administration in cynomolgus monkeys. Alcohol Clin Exp Res (2010) 0.80
Factor II activity is similarly increased in patients with elevated apolipoprotein CIII and in carriers of the factor II 20210A allele. J Am Heart Assoc (2013) 0.79
Reduced apolipoprotein glycosylation in patients with the metabolic syndrome. PLoS One (2014) 0.78
The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it. Lipids Health Dis (2015) 0.76
Antisense inhibition of apoB synthesis with mipomersen reduces plasma apoC-III and apoC-III-containing lipoproteins. J Lipid Res (2012) 0.75
Label-Free Proteome Analysis of Plasma from Patients with Breast Cancer: Stage-Specific Protein Expression. Front Oncol (2017) 0.75
Using primary murine intestinal enteroids to study dietary TAG absorption, lipoprotein synthesis, and the role of apoC-III in the intestine. J Lipid Res (2017) 0.75
Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study. Atherosclerosis (2009) 0.75
Effect of Leptin Administration on Circulating Apolipoprotein CIII levels in Patients With Lipodystrophy. J Clin Endocrinol Metab (2016) 0.75
Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition. J Lipid Res (2017) 0.75
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation (2003) 8.61
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part II. Circulation (2003) 3.94
Lipid-related markers and cardiovascular disease prediction. JAMA (2012) 3.91
Framingham risk function overestimates risk of coronary heart disease in men and women from Germany--results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J (2003) 3.48
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2003) 3.43
[Prospective validation in identical Turkish cohort of two metabolic syndrome definitions for predicting cardiometabolic risk and selection of most appropriate definition]. Anadolu Kardiyol Derg (2007) 2.64
Prediction of risk of coronary events in middle-aged men in the Prospective Cardiovascular Münster Study (PROCAM) using neural networks. Int J Epidemiol (2002) 2.48
Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women--without associated overall health benefit. Atherosclerosis (2006) 2.38
HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest (2004) 2.36
Serum uric acid is a determinant of metabolic syndrome in a population-based study. Am J Hypertens (2006) 2.25
Neck circumference as a measure of central obesity: associations with metabolic syndrome and obstructive sleep apnea syndrome beyond waist circumference. Clin Nutr (2008) 2.12
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol (2008) 1.88
High impact running improves learning. Neurobiol Learn Mem (2006) 1.88
HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis (2002) 1.87
Cell tagging with clinically approved iron oxides: feasibility and effect of lipofection, particle size, and surface coating on labeling efficiency. Radiology (2005) 1.79
High phosphate directly affects endothelial function by downregulating annexin II. Kidney Int (2012) 1.57
Centralized Pan-European survey on the under-treatment of hypercholesterolaemia (CEPHEUS): overall findings from eight countries. Curr Med Res Opin (2010) 1.56
Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol (2006) 1.51
Metabolic syndrome: major impact on coronary risk in a population with low cholesterol levels--a prospective and cross-sectional evaluation. Atherosclerosis (2002) 1.47
FTY720, a synthetic sphingosine 1 phosphate analogue, inhibits development of atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2007) 1.46
The role of European national journals in education. Heart (2009) 1.46
High absolute coronary disease risk among Turks: involvement of risk factors additional to conventional ones. Cardiology (2010) 1.46
Phytanic acid accumulation is associated with conduction delay and sudden cardiac death in sterol carrier protein-2/sterol carrier protein-x deficient mice. J Cardiovasc Electrophysiol (2004) 1.43
PROCAM Study: risk prediction for myocardial infarction using microfluidic high-density lipoprotein (HDL) subfractionation is independent of HDL cholesterol. Clin Chem Lab Med (2008) 1.42
Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. Atherosclerosis (2013) 1.41
[Serum apolipoprotein B is superior to LDL-cholesterol level in predicting incident coronary disease among Turks]. Anadolu Kardiyol Derg (2007) 1.39
Determinants and definition of abdominal obesity as related to risk of diabetes, metabolic syndrome and coronary disease in Turkish men: a prospective cohort study. Atherosclerosis (2006) 1.38
The protective effect of single dose tadalafil in contrast-induced nephropathy: an experimental study. Anatol J Cardiol (2014) 1.38
"Atherogenic index of plasma" (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes, and vascular events. J Clin Lipidol (2010) 1.34
Unsaturated fatty acids suppress the expression of the ATP-binding cassette transporter G1 (ABCG1) and ABCA1 genes via an LXR/RXR responsive element. Atherosclerosis (2006) 1.33
European guidelines on cardiovascular disease and prevention in clinical practice. Atherosclerosis (2003) 1.31
Genome-wide mapping of susceptibility to coronary artery disease identifies a novel replicated locus on chromosome 17. PLoS Genet (2006) 1.29
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient. Diab Vasc Dis Res (2008) 1.27
[European National Society cardiovascular journals. Background, rationale and mission statement of the "editors' club"]. Rev Esp Cardiol (2008) 1.26
Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin (2004) 1.25
Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol (2014) 1.20
Response to Conroy et al. SCORE Project. Eur Heart J (2003) 1.20
Changes in macular pigment optical density and serum concentrations of its constituent carotenoids following supplemental lutein and zeaxanthin: the LUNA study. Exp Eye Res (2006) 1.19
Role of endogenous testosterone concentration in pediatric stroke. Ann Neurol (2009) 1.17
Effect of the interleukin-6 promoter polymorphism (-174 G/C) on the incidence and outcome of sepsis. Crit Care Med (2002) 1.16
Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1. Diabetes (2002) 1.13
Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun (2002) 1.12
Prevalence of cholesteryl ester storage disease. Arterioscler Thromb Vasc Biol (2007) 1.11
HDL-associated lysosphingolipids inhibit NAD(P)H oxidase-dependent monocyte chemoattractant protein-1 production. Arterioscler Thromb Vasc Biol (2008) 1.11
Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol (2002) 1.05
Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Rev Cardiovasc Ther (2005) 1.04
Sex difference in development of diabetes and cardiovascular disease on the way from obesity and metabolic syndrome. Metabolism (2005) 1.02
Relatively high levels of serum adiponectin in obese women, a potential indicator of anti-inflammatory dysfunction: relation to sex hormone-binding globulin. Int J Biol Sci (2008) 1.02
CETP TaqIB polymorphism in Turkish adults: association with dyslipidemia and metabolic syndrome. Anadolu Kardiyol Derg (2008) 1.02
Branched chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells. J Biol Chem (2002) 1.02
Prevalence, incidence, predictors and outcome of type 2 diabetes in Turkey. Anadolu Kardiyol Derg (2006) 1.00
Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks. Am J Hypertens (2008) 1.00
Serum C-reactive protein is an independent risk factor predicting cardiometabolic risk. Metabolism (2008) 0.99
Plasma triglycerides, an independent predictor of cardiovascular disease in men: a prospective study based on a population with prevalent metabolic syndrome. Int J Cardiol (2005) 0.99
Predictors of abdominal obesity and high susceptibility of cardiometabolic risk to its increments among Turkish women: a prospective population-based study. Metabolism (2007) 0.98
Type 2 diabetes mellitus and risk of coronary heart disease: results of the 10-year follow-up of the PROCAM study. Eur J Cardiovasc Prev Rehabil (2007) 0.98
Cell surface localization of ABCG1 does not require LXR activation. Arterioscler Thromb Vasc Biol (2006) 0.96
Low-grade inflammation, and dysfunction of high-density lipoprotein and its apolipoproteins as a major driver of cardiometabolic risk. Metabolism (2010) 0.96
The glu298asp polymorphism in the nitric oxide synthase 3 gene is associated with the risk of ischemic stroke in two large independent case-control studies. Hum Genet (2006) 0.96
Inflammatory markers in age-related maculopathy: cross-sectional analysis from the Muenster Aging and Retina Study. Arch Ophthalmol (2005) 0.96
Apolipoprotein A-I-stimulated apolipoprotein E secretion from human macrophages is independent of cholesterol efflux. J Biol Chem (2004) 0.95
Apolipoprotein A-I activates Cdc42 signaling through the ABCA1 transporter. J Lipid Res (2006) 0.94
Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids. Trends Cardiovasc Med (2005) 0.94
Impaired platelet activation in familial high density lipoprotein deficiency (Tangier disease). J Biol Chem (2004) 0.94
Serum sex hormone-binding globulin, a determinant of cardiometabolic disorders independent of abdominal obesity and insulin resistance in elderly men and women. Metabolism (2007) 0.93
Involvement of Cdc42 signaling in apoA-I-induced cholesterol efflux. J Biol Chem (2003) 0.92
Smoking inhibits visceral fat accumulation in Turkish women: relation of visceral fat and body fat mass to atherogenic dyslipidemia, inflammatory markers, insulin resistance, and blood pressure. Metabolism (2009) 0.91
High density lipoprotein-associated lysosphingolipids reduce E-selectin expression in human endothelial cells. Biochem Biophys Res Commun (2003) 0.91
Haemoglobin-related mortality in patients undergoing percutaneous coronary interventions. Eur Heart J (2003) 0.91
ADP-ribosylation factor (ARF)-like 7 (ARL7) is induced by cholesterol loading and participates in apolipoprotein AI-dependent cholesterol export. FEBS Lett (2004) 0.91
Expression of ATP binding cassette-transporter ABCG1 prevents cell death by transporting cytotoxic 7beta-hydroxycholesterol. FEBS Lett (2007) 0.91
Cross-sectional study of complement C3 as a coronary risk factor among men and women. Clin Sci (Lond) (2005) 0.90
The impact of dietary fat composition on serum leptin concentrations in healthy nonobese men and women. J Clin Endocrinol Metab (2002) 0.90
Apolipoprotein E interrupts interleukin-1beta signaling in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2007) 0.89
Grade of chronic renal failure, and acute and long-term outcome after percutaneous coronary interventions. Kidney Int (2003) 0.89
Impaired protection against diabetes and coronary heart disease by high-density lipoproteins in Turks. Metabolism (2009) 0.89
Visceral adipose tissue and body fat mass: predictive values for and role of gender in cardiometabolic risk among Turks. Nutrition (2009) 0.89
Effects of dietary alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid on parameters of glucose metabolism in healthy volunteers. Ann Nutr Metab (2008) 0.88
Predictors for contrast media-induced nephropathy and long-term survival: prospectively assessed data from the randomized controlled Dialysis-Versus-Diuresis (DVD) trial. Can J Cardiol (2008) 0.87
Hemolysis and infective endocarditis in a mitral prosthetic valve. Turk Kardiyol Dern Ars (2010) 0.87
Lifestyle and metabolic determinants of incident hypertension, with special reference to cigarette smoking: a longitudinal population-based study. Am J Hypertens (2008) 0.87
Relation between fragmented QRS and collateral circulation in patients with chronic total occlusion without prior myocardial infarction. Anadolu Kardiyol Derg (2011) 0.87
Abdominal obesity with hypertriglyceridaemia, lipoprotein(a) and apolipoprotein A-I determine marked cardiometabolic risk. Eur J Clin Invest (2013) 0.87
Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system. Cardiology (2005) 0.87
Dietary mono- and polyunsaturated fatty acids similarly affect LDL size in healthy men and women. J Nutr (2002) 0.86
Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population. Metabolism (2009) 0.86
Independent prediction of metabolic syndrome by plasma fibrinogen in men, and predictors of elevated levels. Int J Cardiol (2008) 0.85
Follicular fluid high density lipoprotein-associated sphingosine 1-phosphate is a novel mediator of ovarian angiogenesis. J Biol Chem (2005) 0.85